Dishman Carbogen Amcis Limited

NSEI:DCAL Stock Report

Market Cap: ₹29.9b

Dishman Carbogen Amcis Past Earnings Performance

Past criteria checks 0/6

Dishman Carbogen Amcis's earnings have been declining at an average annual rate of -63.1%, while the Life Sciences industry saw earnings growing at 15.8% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-63.1%

Earnings growth rate

-62.8%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate5.6%
Return on equity-4.4%
Net Margin-10.3%
Next Earnings Update13 Nov 2024

Recent past performance updates

Recent updates

The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet

Oct 15
The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet

Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge

Jun 01
Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge

Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Feb 25
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dec 29
Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?

Jun 22
Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?

Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?

Feb 14
Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?

Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky

Jun 22
Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky

Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings

May 18
Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings

Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet

Mar 14
Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet

We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt

Aug 23
We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt

Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching

Apr 29
Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching

Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet

Mar 16
Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet

A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns

Feb 23
A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns

How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?

Feb 05
How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?

Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?

Jan 23
Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?

What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Jan 10
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dec 23
Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dec 05
Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Nov 17
Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate

If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%

Oct 23
If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%

What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Sep 27
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?

Sep 06
Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk

Aug 03
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk

Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings

Jul 20
Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings

Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings

Jul 06
Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings

Revenue & Expenses Breakdown

How Dishman Carbogen Amcis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:DCAL Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2424,162-2,48012,2990
31 Mar 2426,158-1,53412,1610
31 Dec 2325,796-1,54211,5100
30 Sep 2325,683-47711,1470
30 Jun 2325,957-16810,7520
31 Mar 2324,129-29810,3820
31 Dec 2223,634-3710,4520
30 Sep 2222,856-15210,3000
30 Jun 2221,306609,9880
31 Mar 2221,4071809,8890
31 Dec 2121,013-7249,5800
30 Sep 2120,078-1,2399,2730
30 Jun 2119,884-1,2779,0720
31 Mar 2119,120-1,6518,8220
31 Dec 2018,9464198,6400
30 Sep 2019,6839088,3220
30 Jun 2019,9611,2467,9240
31 Mar 2020,4361,5857,7200
31 Dec 1921,8121,8378,2280
30 Sep 1921,1792,0228,0860
30 Jun 1920,9832,0507,3610
31 Mar 1920,5862,1037,7180
31 Dec 1818,9241,8627,3310
30 Sep 1818,7451,7687,1320
30 Jun 1818,8261,8126,5410
31 Mar 1816,9481,5466,7660
31 Dec 1717,8541,5376,8440
30 Sep 1716,8401,3836,5680
30 Jun 1716,7781,2825,9440
31 Mar 1717,1941,4546,4960
31 Dec 1612,0389534,240-35
31 Mar 16689510
31 Mar 150-500

Quality Earnings: DCAL is currently unprofitable.

Growing Profit Margin: DCAL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DCAL is unprofitable, and losses have increased over the past 5 years at a rate of 63.1% per year.

Accelerating Growth: Unable to compare DCAL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DCAL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (32.8%).


Return on Equity

High ROE: DCAL has a negative Return on Equity (-4.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies